Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jean-Yves Maziere"'
Autor:
Laura Wallace, Jean-Yves Maziere, M. Soledad Cepeda, Paul Coplan, Gregory P Wedin, Nathan W. Kopper
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
Objective. Opioid abuse is a serious public health concern. In response, the Food and Drug Administration (FDA) determined that a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioids was necessary to ens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37dda6e242d2dc0dc3981bcc56f82683
http://europepmc.org/articles/PMC5283702
http://europepmc.org/articles/PMC5283702
Autor:
Jean-Yves Maziere, BA Victoria Divino, Paul Coplan, ScD, Mba, Mph, M. Soledad Cepeda, Rolin L Wade, Yingli Yuan
Publikováno v:
Journal of opioid management. 13(3)
Objective: The Food and Drug Administration approved the extended-release/long-acting (ER/LA) opioid analgesics risk evaluation and mitigation strategies (REMS) in July 2012 to educate healthcare providers and patients about safe and appropriate opio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515956ce4db80866e50d45a2a759ee9e
https://pubmed.ncbi.nlm.nih.gov/28829517
https://pubmed.ncbi.nlm.nih.gov/28829517
Autor:
Richard C. Dart, Gregory P Wedin, Becki Bucher Bartelson, Jean-Yves Maziere, M. Soledad Cepeda, Paul Coplan, Jody L. Green, M. Claire Le Lait
Publikováno v:
Pharmacoepidemiology and drug safety. 26(9)
Purpose An unintended consequence of extended-release (ER) and long-acting (LA) prescription opioids is that these formulations can be more attractive to abusers than immediate-release (IR) formulations. The US Food and Drug Administration recognized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::610b5c6ab08936a5a9550d8c80af083b
https://pubmed.ncbi.nlm.nih.gov/28758289
https://pubmed.ncbi.nlm.nih.gov/28758289